In a sub-analysis of the TWILIGHT trial, which looked only at patients with acute coronary syndrome (ACS), researchers confirmed that dropping aspirin after 3 months of dual antiplatelet therapy (DAPT) with ticagrelor following percutaneous coronary intervention (PCI) lowers bleeding risk without increasing the rate of ischaemic events. The benefit observed with ticagrelor monotherapy was independent of risk levels or whether the patients had non-ST elevation myocardial infarction (NSTEMI) or unstable angina at presentation.
Prof. Usman Baber (Icahn School of Medicine at Mount Sinai, USA) provided the rationale behind this particular sub-analysis: “The basis for DAPT in ACS really comes from trials conducted almost 20 years ago showing that it is superior to aspirin,” but he noted that “one of the challenges we have with the provision of antiplatelet therapy right now is that a lot of patients w...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Icosapent ethyl plus statins reduces total plaque volume Next Article
Off-the-shelf natural killer cells »
Table of Contents: AHA 2019
New Approaches to CVD Risk Reduction
Interventional Management for Acute Coronary Syndrome
Results for the Ischemia Trials: To Intervene or Not to Intervene
Controversies in Contemporary Management of Aortic Stenosis
Guidelines: Updates and Controversies
Trials in Electrophysiology and Left Ventricular Function
New Frontiers in Lipid Therapy
Challenges in Heart Failure Management
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.